Quanterix

208 articles about Quanterix

• Quanterix to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

  9/5/2023

  Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will take part in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on September 13, 2023 at 3:35 p.m. ET.

• Quanterix Appoints Vandana Sriram as Chief Financial Officer

  8/9/2023

  Quanterix Corporation today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023.

• Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

  7/31/2023

  Quanterix’s Simoa ® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients.

• Quanterix to Report Second Quarter 2023 Financial Results on August 8, 2023

  7/20/2023

  Quanterix Corporation today announced that it will report financial results for the second quarter 2023 before the market opens on Tuesday, August 8, 2023, and will host a webcast and conference call on the same day at 8:30 a.m. E.T.

• Quanterix Launches LucentAD Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients

  7/6/2023

  Quanterix Corporation, a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, announced it has launched LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with the early signs of Alzheimer’s disease.

• Quanterix Releases Operating Results for First Quarter 2023

  5/9/2023

  Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced financial results for the three months ended March 31, 2023.

• Quanterix’s First Quarter 2023 Earnings Conference Call

  5/2/2023

  Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced it will host a conference call on Tuesday, May 9, 2023, to discuss its first quarter 2023 financial results.

• Quanterix to Participate in Barclays Global Healthcare Conference - March 23, 2023

  3/8/2023

  Quanterix Corporation today announced that Chief Executive Officer Masoud Toloue will present at Barclays Global Healthcare Conference on Wednesday, March 15, 2023 at 4:35 p.m., EDT.

• Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations

  3/6/2023

  Quanterix Corporation today announced financial results for the fourth quarter and twelve months ended December 31, 2022.

• Quanterix to Present at Cowen’s 43rd Annual Health Care Conference

  2/28/2023

  Quanterix Corporation today announced that Chief Executive Officer Masoud Toloue will present at Cowen’s 43rd Annual Health Care Conference. Quanterix’s session will take place on Tuesday, March 7, 2023, at 9:50 a.m. EST and will be made available to attendees and, via webcast, the general public.

• Quanterix Fourth Quarter Earnings and Full Year 2022 Financial Results Conference Call

  2/24/2023

  Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced it will host a conference call on Monday, March 6, 2023, to discuss its fourth quarter earnings and full year 2022 financial results.

• Quanterix Announces Appointment of Brian Blaser to Board of Directors

  1/9/2023

  Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023.

• Quanterix to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection, announced that Chief Executive Officer Masoud Toloue will be presenting at the 41st Annual J.P. Morgan Healthcare Conference.

• Quanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services Forum

  11/10/2022

  Quanterix Corporation today announced that President and Chief Executive Officer Masoud Toloue and Chief Financial Officer Michael Doyle will present at the CG MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 17, 2022 at 4:30 p.m. EST in Boston, MA.

• Quanterix Corporation Releases Operating Results for Second Quarter 2022, Announces Business Re-Alignment Plan and Revises 2022 Guidance

  8/8/2022

  Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced operating results for the three months ended June 30, 2022.

• Quanterix Announces the Resignation of Kevin Hrusovsky as Executive Chairman of Board of Directors

  8/8/2022

  Quanterix Corporation, a company expanding the limits of exploration with ultrasensitive biomarker detection, announced that E. Kevin Hrusovsky is stepping down as Executive Chairman of its Board of Directors.

• Quanterix Announces Appointment of Karen A. Flynn to Board of Directors

  6/6/2022

  Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.

• Quanterix Corporation Releases Operating Results for First Quarter 2022

  5/10/2022

  Quanterix reports continued revenue growth as it scales to support transformational advances in neurology research.

• Quanterix Corporation to Release First Quarter 2022 Financial Results on May 10, 2022

  5/3/2022

  Quanterix Corporation today announced that it will release its financial results for first quarter 2022 before the start of trading on May 10, 2022.

• Quanterix Granted Breakthrough Device Designation from U.S. FDA for NfL Test for Multiple Sclerosis

  4/22/2022

  Quanterix Corporation today announced that its Simoa® neurofilament light chain (NfL) plasma test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration.